01 2Voltaren
02 1Voltaren (Excluding Other Divisions)
03 6Voltaren/Cataflam
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 360
2019 Revenue in Millions : 417
Growth (%) : -14
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 373
2020 Revenue in Millions : 360
Growth (%) : 4
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 334
2021 Revenue in Millions : 373
Growth (%) : -10
Main Therapeutic Indication : Others
Currency : USD
2014 Revenue in Millions : -6.40%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Others
Currency : USD
2015 Revenue in Millions : 632
2014 Revenue in Millions : 558
Growth (%) : -12%
Main Therapeutic Indication : Anti-Inflammatory
Currency : USD
2016 Revenue in Millions : 525
2015 Revenue in Millions : 558
Growth (%) : -6
Main Therapeutic Indication : Anti-inflammatory
Currency : USD
2017 Revenue in Millions : 465
2016 Revenue in Millions : 525
Growth (%) : -11
Main Therapeutic Indication : Anti-Inflammatory
Currency : USD
2018 Revenue in Millions : 445
2017 Revenue in Millions : 465
Growth (%) : -4%
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 417
2018 Revenue in Millions : 445
Growth (%) : -6
LOOKING FOR A SUPPLIER?